Δ-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor- mediated, cytokine-dependent pathway

Journal of Immunology

Volumn 165, Issue 1, 2000, Pages 373-380

  Zhu, Li X ^a   Sharma, Sherven ^a,b   Stolina, Marina ^a   Gardner, Brian ^a   Roth, Michael D ^a   Tashkin, Donald P ^a   Dubinett, Steven M ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; DRONABINOL; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRAFT; CARCINOGENICITY; CONTROLLED STUDY; IMMUNE RESPONSE; IMMUNOCOMPETENCE; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR IMMUNITY;

EID: 0034235808     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.1.373     Document Type: Article

References (91)

1. Razdan, R. K. 1986. Structure-activity relationships in cannabinoids. Pharmacol. Rev. 38:75.
2. Baldwin, G. C., D. P. Tashkin, D. M. Buckley, A. N. Park, S. M. Dubinett, and M. D. Roth. 1997. Marijuana and cocaine impair alveolar macrophage function and cytokine production. Am. J. Respir. Crit. Care Med. 156:1606.
3. Zheng, Z. M., and S. C. Specter. 1996. Δ-9-Tetrahydrocannabinol suppresses tumor necrosis factor α maturation and secretion but not its transcription in mouse macrophages. Int. J. Immunopharmacol. 18:53.
4. McCoy, K. L., D. Gainey, and G. A. Cabral. 1995. Δ-9-Tetrahydrocannabinol modulates antigen processing by macrophages. J. Pharmacol. Exp. Ther. 273: 1216.
5. McCoy, K. L., M. Matveyeva, S. J. Carlisle, and G. A. Cabral. 1999. Cannabinoid inhibition of the processing of intact lysozyme by macrophages: evidence for CB2 receptor participation. J. Pharmacol. Exp. Ther. 289:1620.
6. Kusher, D. I., L. O. Dawson, A. C. Taylor, and J. Y. Djeu. 1994. Effect of the psychoactive metabolite of marijuana, Δ-9-tetrahydrocannabinol (THC), on the synthesis of tumor necrosis factor by human large granular lymphocytes. Cell. Immunol. 154:99.
7. Klein, T. W., C. Newton, and H. Friedman. 1998. Cannabinoid receptors and immunity. Immunol. Today 19:373.
8. Kaminski, N. E. 1996. Immune regulation by cannabinoid compounds through the inhibition of the cyclic AMP signaling cascade and altered gene expression. Biochem. Pharmacol. 52:1133.
9. Hollister, L. E. 1988. Marijuana and immunity. J. Psychoactive Drugs 20:3.
10. Klein, T. W., Y. Kawakami, C. Newton, and H. Friedman. 1991. Marijuana components suppress induction and cytolytic function of murine cytotoxic T cells in vitro and in vivo. J. Toxicol. Environ. Health 32:465.
11. Bhargava, H. N., R. V. House, S. N. Thoral, and P. T. Thomas. 1996. Cellular immune function in mice tolerant to or abstinent from 1-trans-Δ-9-tetrahydrocannabinol. Pharmacology 52:271.
12. Munro, S., K. L. Thomas, and M. Abu-Shaar. 1993. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61.
13. O'Garra, A. 1998. Cylokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 8:275.
14. Hagenbaugh, A., S. Sharma, S. Dubinett, S. H.-Y. Wei, R. Aranda, H. Cheroutre, D. Fowell, S. Binder, B. Tsao, R. Locksley, et al. 1997. Altered immune responses in IL-10 transgenic mice. J. Exp. Med. 185:2101.
15. Mosmann, T. R., and R. L. Coffman. 1989. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145.
16. Newton, C. A., T. W. Klein, and H. Friedman. 1994. Secondary immunity to Legionella pneumophila and Th1 activity are suppressed by Δ-9-tetrahydrocannabinol injection. Infect. Immun. 62:4015.
17. Klein, T. W., C. Newton, and H. Friedman. 1996. Cannabinoids and immunity to Legionella pneumophila infection. Adv. Exp. Med. Biol. 402:103.
18. Sogn, J. A. 1998. Tumor immunology: the glass is half full. Immunity 9:757.
19. Hahne, M., D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L. E. French, P. Schneider, T. Bornard, A. Fontana, D. Lienard, et al. 1996. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274:1363.
20. Huang, M., J. Wang, P. Lee, S. Sharma, J. T. Mao, H. Meissner, K. Uyemura, R. Modlin, J. Wollman, and S. M. Dubinett. 1995. Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res. 55:3847.
21. Kim, J., R. L. Modlin, R. L. Moy, S. M. Dubinett, T. McHugh, B. J. Nickoloff, and K. Uyemura. 1995. IL-10 production in cutaneous basal and squamous cell carcinomas: a mechanism for evading the local T cell immune response. J. Immunol. 155:2240.
22. Staveley-O'Carroll, K., E. Sotomayor, J. Montgomery, I. Borrello, L. Hwang, S. Fein, D. Pardoll, and H. Levitsky. 1998. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 95:1178.
23. Speiser, D. E., R. Miranda, A. Zakarian, M. F. Bachmann, K. McKall-Faienza, B. Odermatt, D. Hanahan, R. M. Zinkernagel, and P. S. Ohashi. 1997. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med. 186:645.
24. Huang, M., M. Stolina, S. Sharma, J. Mao, L. Zhu, P. Miller, J. Wollman, H. Herschman, and S. Dubinett. 1998. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulalion of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res. 58:1208.
25. Miller, P. W., S. Sharma, M. Stolina, L. H. Butterfield, J. Luo, Y. Lin, M. Dohadwala, R. K. Batra, L. Wu, J. S. Economou, and S. M. Dubinett. 2000. Intratumoral administration of adenoviral interleukin 7 gene-modilied dendritic cells augments specitic antitumor immunity and achieves tumor eradication. Hum. Gene Ther. 11:53.
26. Stolina, M., S. Sharma, Y. Lin, M. Dohadwala, B. Gardner, J. Luo, L. Zhu, M. Kronenberg, P. Miller, J. Lee, and S. Dubinett. 2000. Specific inhibition of cyclooxygenase 2 restores antitumor immunity by altering the balance of IL-10 and IL-12 synthesis. J. Immunol. 164:361.
27. Sharma, S., P. Miller, M. Stolina, L. Zhu, M. Huang, R. Paul, and S. Dubinett. 1997. Multi-component gene therapy vaccines for lung cancer: effective eradication of established murine tumors in vivo with interleukin 7/herpes simplex thymidine kinase-transduced autologous tumor and ex vivo-activated dendritic cells. Gene Ther. 4:1361.
28. Rinaldi-Carmona, M., F. Barth, J. Millan, J. M. Derocq, P. Casellas, C. Congy, D. Oustric, M. Sarran, M. Bouaboula, B. Calandra, et al. 1998. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284:644.
29. SAS Institute, I. 1990. SAS/Stat User's Guide, Version 6, Vol. 1 and 2. Cary, NC.
30. Rohrer, J. W., and J. H. Coggin Jr. 1995. CD8 T cell clones inhibit antitumor T cell function by secreting IL-10. J. Immunol. 155:5719.
31. Proft, T., and J. Fraser. 1998. Superantigens: just like peptides only different. J. Exp. Med. 187:819.
32. Miller, C., J. A. Ragheb, and R. H. Schwartz. 1999. Anergy and cytokine-mediated suppression as distinct superantigen-induced tolerance mechanisms in vivo. J. Exp. Med. 190:53.
33. Torre-Amione, G., R. D. Beauchamp, H. Koeppen, B. H. Park, H. Schreiber, H. L. Moses, and D. A. Rowley. 1990. A highly immunogenic tumor transfected with a murine transforming growth factor type β1 cDNA escapes immune surveillance. Proc. Natl. Acad. Sci. USA 87:1486.
34. Fiorentino, D. F., A. Zlotnik, T. R. Mosmann, M. Howard, and A. Ogarra. 1991. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147: 3815.
35. Mitra, R. S., T. A. Judge, F. O. Nestle, L. A. Turka, and B. J. Nickoloff. 1995. Psoriatic skin-derived dendritic cell function is inhibited by exogenous IL-10. J. Immunol. 154:2668.
36. Mosmann, T., and K. W. Moore. 1991. The role of IL-10 in cross-regulation of TH1 and TH2 responses. Immunol. Today 12:A49.
37. Fiorentino, D. F., A. Zlotnik, P. Vieira, T. R. Mosmann, M. Howard, K. W. Moore, and A. O'Garra. 1991. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J. Immunol. 146:3444.
38. Pardoux, C., C. Asselin-Paturel, J. Chehimi, F. Gay, F. Mami-Chouaib, and S. Chouaib. 1997. Functional interaction between TGF-β and IL-12 in human primary allogeneic cytotoxicity and proliferative response. J. Immunol. 158:136.
39. Fargeas, C., C. Y. Wu, T. Nakajima, D. Cox, T. Nutman, and G. Delespesse. 1992. Differential effect of transforming growth factor β on the synthesis of Th1- and Th2-like lymphokines by human T lymphocytes. Eur. J. Immunol. 22:2173.
40. Bogdan, C., and C. Nathan. 1993. Modulation of macrophage function by transforming growth factor β, interleukin-4, and interleukin-10. Ann. NY Acad. Sci. 685:713.
41. Bodmer, S., K. Strommer, K. Frei, C. Siepl, N. de Tribolet, I. Heid, and A. Fontana. 1989. Immunosuppression and transforming growth factor-β in glioblastoma: preferential production of transforming growth factor-β2. J. Immunol. 143:3222.
42. Siepl, C., S. Bodmer, K. Frei, H. R. MacDonald, R. De Martin, E. Hofer, and A. Fontana. 1988. The glioblastoma-derived T cell suppressor factor/transforming growth factor-β2 inhibits T cell growth without affecting the interaction of interleukin 2 with its receptor. Eur. J. Immunol. 18:593.
43. Bejarano, M. T., R. De Waal Malefyt, J. S. Abrams, M. Bigler, R. Baccheta, J. E. De Vries, and M. G. Roncarolo. 1992. Interleukin-10 inhibits allogenic proliferative and cytotoxic T-cell responses generated in primary mixed lymphocyte cultures. Int. Immunol. 4:1389.
44. i protein modulation induced by a selective inverse agonist for the peripheral cannabinoid receptor CB2: implication for intracellular signalization cross-regulation. Mol. Pharmacol. 55:473.
45. Massi, P., P. Sacerdote, W. Ponti, D. Fuzio, B. Manfredi, D. Vigano, T. Rubino, M. Bardotti, and D. Parolaro. 1998. Immune function alterations in mice tolerant to Δ9-tetrahydrocannabinol: functional and biochemical parameters. J. Neuroimmunol. 92:60.
46. Galve-Roperh, I., C. Sanchez, M. L. Cortes, T. G. del Pulgar, M. Izquierdo, and M. Guzman. 2000. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat. Med. 6:313.
47. Klein, T. W., H. Friedman, and S. Specter. 1998. Marijuana, immunity and infection. J. Neuroimmunol. 83:102.
48. Cabral, G. A., and D. A. Dove Pettit. 1998. Drugs and immunity: cannabinoids and their role in decreased resistance to infectious disease. J. Neuroimmunol. 83:116.
49. Arata, S., T. Klein, C. Newton, and H. Friedman. 1991. Tetrahydrocannabinol treatment suppresses growth restriction of Legionella pneumophila in murine macrophage cultures. Life Sci. 49:473.
50. Ashfaq, M., E. S. Waston, and H. Elsohly. 1987. The effect of subacute marijuana smoke inhalation on experimentally induced dermonecrosis by S. aureus infection. Immunopharmacol. Immunotoxicol. 9:319.
51. Bradley, S., A. Munson, W. Dewey, and L. Harris. 1977. Enhanced susceptibility of mice to combination of Δ 9-tetrahydrocannabinol and live or killed Gram-negative bacteria. Infect. Immun. 2:325.
52. Cabral, G., and E. Mishkin. 1989. Δ 9-Tetrahydrocannabinol inhibits macrophage protein expression in response to bacterial immunomodulators. J. Toxicol. Environ. Health 26:175.
53. Cabral, G., and R. Vasquez. 1992. Δ9-Tetrahydrocannabinol suppresses macrophage extrinsic antiherpes virus activity. Proc. Soc. Exp. Biol. Med. 199:255.
54. Fischer-Stenger, K., A. Updegrove, and G. Cabral. 1992. Δ 9-Tetrahydrocannabinol decreases cytotoxic T lymphocyte activity to herpes simplex virus type 1-infected cells. Proc. Soc. Exp. Biol. Med. 200:422.
55. 2. J. Immunol. 153:1674.
56. Maeda, H., and A. Shiraishi. 1996. TGF-β contributes to the shift toward Th2-type responses through direct and IL-10 mediated pathways in tumor-bearing mice. J. Immunol. 156:73.
57. Seo, N., Y. Tokura, M. Takigawa, and K. Egawa. 1999. Depletion of IL-10- and TGF-β-producing regulatory γΔ T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells. J. Immunol. 163:242.
58. De Visser, K. E., and W. M. Kast. 1999. Effects of TGF-β on the immune system: implications for cancer immunotherapy. Leukemia 13:1188.
59. Matsuda, M., F. Salazar, M. Petersson, G. Masucci, J. Hansson, P. Pisa, Q. Zhang, M. G. Masucci, and R. Kiessling. 1994. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and down-regulates HLA class 1 expression. J. Exp. Med. 180:2371.
60. Salazar-Onfray, F., M. Petersson, L. Franksson, M. Matsuda, T. Blankenstein, K. Kärre, and R. Kiessling. 1995, IL-10 converts mouse lymphoma cells to a CTL-resistant, NK-sensitive phenotype with low but peptide-inducible MHC class I expression. J. Immunol. 154:6291.
61. Qin, Z., G. Noffz, M. Mohaupt, and T. Blankenstein, 1997. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. J. Immunol. 159:770.
62. Sundstedt, A., I. Hoiden, A. Rosendahl, T. Kalland, N. van Roijen, and M. Dohlsten. 1997. Immunoregulatory role of IL-10 during superantigen-induced hyporesponsiveness in vivo. J. Immunol. 158:180.
63. Assenmacher, M., M. Lohning, A. Scheffold, R. A. Manz, J. Schmitz, and A. Radbruch. 1998. Sequential production of IL-2, IFN-γ and IL-10 by individual staphylococcal enterotoxin B-activated T helper lymphocytes. Eur. J. Immunol. 28:1534.
64. Florquin, S., Z. Amraoui, D. Abramowicz, and M. Goldman. 1994. Systemic release and protective role of IL-10 in staphylococcal enterotoxin B-induced shock in mice. J. Immunol. 153:2618.
65. Bean, A. G., R. A. Freiberg, S. Andrade, S. Menon, and A. Zlotnik. 1993. Interleukin 10 protects mice against staphylococcal enterotoxin B-induced lethal shock. Infect. Immun. 61:4937.
66. Crisi, G. M., L. Santambrogio, G. M. Hochwald, S. R. Smith, J. A. Carlino, and G. J. Thorbecke. 1995. Staphylococcal enterotoxin B and tumor-necrosis factor-α-induced relapses of experimental allergic encephalomyelitis: protection by transforming growth factor-β and interleukin-10. Eur. J. Immunol. 25:3035.
67. 2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. J. Immunol. 157:5512.
68. Klein, T. W., C. Newton, and H. Friedman. 1998. Cannabinoid receptors and the cytokine network. Adv. Exp. Med. Biol. 437:215.
69. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389:737.
70. Letterio, J. J., and A. B. Roberts. 1998. Regulation of immune responses by TGF-β. Annu. Rev. Immunol. 16:137.
71. Takeuchi, M., P. Alard, and J. Streilein. 1998. TGF-β promotes immune deviation by altering accessory signals of antigen-presenting cells. J. Immunol. 160: 1589.
72. King, C., J. Davies, R. Mueller, M. S. Lee, T. Krahl, B. Yeung, E. O'Connor, and N. Sarvetnick. 1998. TGF-β1 alters APC preference, polarizing islet antigen responses toward a Th2 phenotype. Immunity 8:601.
73. D'Orazio, T., and J. Y. Niederkorn. 1998. A novel role for TGF-β and IL-10 in the induction of immune priviledge. J. Immunol. 160:2089 .
74. Fischer-Stenger, K., D. A. Dove Pettit, and G. A. Cabral. 1993. Δ 9-Tetrahydrocannabinol inhibition of tumor necrosis factor-α: suppression of post-translational events. J. Pharmacol. Exp. Ther. 267:1558.
75. Klein, T. W., C. A. Newton, R. Widen, and H. Friedman. 1985. The effect of Δ-9-tetrahydrocannabinol and 11-hydroxy-Δ-9-tetrahydrocannabinol on T-lymphocyte and B-lymphocyte mitogen responses. J. Immunopharmacol. 7:451.
76. Matsuda, L. A., S. J. Lolait, M. J. Brownstein, A. C. Young, and T. I. Bonner. 1990. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561.
77. Matsuda, L. A. 1997. Molecular aspects of cannabinoid receptors. Crit. Rev. Neurobiol. 11:143.
78. Sinha, D., T. I. Bonner, N. R. Bhat, and L. A. Matsuda. 1998. Expression of the CB1 cannabinoid receptor in macrophage-like cells from brain tissue: immunochemical characterization by fusion protein antibodies. J. Neuroimmunol. 82:13.
79. Kaminski, N. E. 1998. Inhibition of the cAMP signaling cascade via cannabinoid receptors: a putative mechanism of immune modulation by cannabinoid compounds. Toxicol. Lett. 102:59.
80. Schatz, A. R., M. Lee, R. B. Condie, J. T. Pulaski, and N. E. Kaminski. 1997. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol. Appl. Pharmacol. 142:278.
81. Parolaro, D. 1999. Presence and functional regulation of cannabinoid receptors in immune cells. Life Sci. 65:637.
82. Voth, E., and R. Schwartz. 1997. Medicinal application of Δ-9-tetrahydrocannibinol and marijuana. Ann. Intern. Med. 126:791.
83. Kassirer, J. 1997. Federal foolishness and marijuana. N. Engl. J. Med. 336:336.
84. Hoffmann, D., D. Brunnemann, G. Gori, and E. Wynder. 1975. On the carcinogenicity of marijuana smoke. Recent Adv. Phytochem. 9:63.
85. Denissenko, M., A. Pao, M.-s. Tang, and G. Pfeifer. 1996. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science 274:430.
86. Wu, T.-C., D. Tashkin, B. Djahed, and J. Rose. 1988. Pulmonary hazards of smoking marijuana as compared with tobacco. N. Engl. J. Med. 318:347.
87. Tashkin, D. 1993. Is frequent marijuana smoking harmful to health? West. J. Med. 158:635.
88. Taylor, F. M. d. 1988. Marijuana as a potential respiratory tract carcinogen: a retrospective analysis of a community hospital population. South. Med. J. 81: 1213.
89. Sridhar, K., W. J. Raub, N. Weatherby, L. Metsch, H. Surratt, J. Inciardi, R. Duncan, R. Anwyl, and C. McCoy. 1994. Possible role of marijuana smoking as a carcinogen in the development of lung cancer at a young age. J. Psychoactive Drugs 26:285.
90. Donald, P. 1991. Marijuana and upper aerodigestive tract malignancy in young patients. In Physiopathology of Illicit Drugs: Cannabis, Cocaine, Opiates. Advances in the Biosciences. G. G. Nahas and C. Latour, eds. Pergamon Press, New York.
91. Zhang, Z. F., H. Morgenstern, M. R. Spitz, D. P. Tashkin, G. P. Yu, J. R. Marshall, T. C. Hsu, and S. P. Schantz. 1999. Marijuana use and increased risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol. Biomarkers Prev. 8:1071.